Pfizer Inc (PFE)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 2.02 | 2.10 | 2.50 | 2.46 | 2.80 | 2.89 | 2.42 | 3.23 | 3.87 | 3.66 | 3.71 | 3.68 | 3.42 | 2.80 | 1.87 | 1.41 | 1.26 | 1.05 | 1.15 | 1.21 |
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Working capital turnover | 8.64 | 5,009.42 | — | 28.72 | — | 1.60 | 2.01 | 6.88 | 11.00 | 3.83 | 5.05 | 6.11 | 4.79 | 4.31 | 4.36 | 3.90 | 5.21 | 3.58 | 3.59 | 59.74 |
Pfizer Inc's inventory turnover ratio has shown a consistent increase over the years, indicating that the company is managing its inventory more efficiently. The ratio increased from 1.21 in March 2020 to 2.02 in December 2024, with some fluctuations in between.
The receivables turnover ratio data is missing for all the periods provided, which makes it difficult to assess how quickly Pfizer is collecting its receivables from customers.
Similarly, the payables turnover data is also missing, which deprives us of insights into how effectively Pfizer is managing its payables and its relationships with suppliers.
The working capital turnover ratio has shown significant variability, ranging from 1.60 in September 2023 to an exceptionally high figure of 5,009.42 in September 2024. Such extreme fluctuations in the working capital turnover may warrant further investigation into the company's liquidity management practices and operational efficiency.
Overall, while the inventory turnover ratio paints a positive picture of Pfizer's operational efficiency in managing inventory, the absence of data for receivables and payables turnover ratios, coupled with the erratic behavior of the working capital turnover ratio, highlights the importance of a more comprehensive analysis to provide a complete picture of Pfizer's activity ratios and operational performance.
Average number of days
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 180.81 | 173.99 | 146.01 | 148.27 | 130.59 | 126.10 | 150.56 | 112.98 | 94.30 | 99.64 | 98.45 | 99.13 | 106.77 | 130.57 | 195.48 | 259.63 | 290.57 | 346.33 | 316.74 | 302.48 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Based on the provided data, Pfizer Inc's days of inventory on hand (DOH) has shown a fluctuating trend over the period from March 31, 2020, to December 31, 2024. The DOH started at a relatively high level, indicating slow inventory turnover, but then gradually decreased before experiencing some fluctuations in later periods.
In March 2024, Pfizer had 148.27 days of inventory on hand, which declined to 146.01 days by June 2024. However, by September 2024, the DOH increased to 173.99 days before rising further to 180.81 days by December 2024. These fluctuations suggest potential challenges in managing inventory levels efficiently.
Unfortunately, data on days of sales outstanding (DSO) and number of days of payables are not available, limiting the comprehensive analysis of Pfizer Inc's activity ratios. Monitoring and managing these metrics can provide insights into the company's operational efficiency, cash flow management, and overall liquidity position.
See also:
Pfizer Inc Short-term (Operating) Activity Ratios (Quarterly Data)
Long-term
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | — | — | — | 2.93 | 2.68 | 3.84 | 4.46 | 5.45 | 6.17 | 6.47 | 6.65 | 6.13 | 5.48 | 4.80 | 4.03 | 3.58 | 3.43 | 3.38 | 3.49 | 3.61 |
| Total asset turnover | 0.30 | 0.27 | 0.26 | 0.25 | 0.26 | 0.32 | 0.35 | 0.48 | 0.51 | 0.51 | 0.52 | 0.50 | 0.45 | 0.39 | 0.34 | 0.32 | 0.31 | 0.27 | 0.28 | 0.30 |
The Fixed Asset Turnover ratio for Pfizer Inc has shown a fluctuating trend over the years, starting at 3.61 in March 2020, decreasing to 2.68 by December 2023, and then slightly increasing to 2.93 by March 2024. This ratio measures how efficiently the company is generating sales from its fixed assets.
On the other hand, the Total Asset Turnover ratio has also been fluctuating, starting at 0.30 in March 2020, reaching a peak of 0.52 in June 2022, before declining to 0.30 by December 2024. This ratio indicates how well the company is using its total assets to generate revenues.
Overall, the Fixed Asset Turnover ratio has been higher than the Total Asset Turnover ratio for Pfizer Inc, which suggests that the company is more efficient in generating sales from its fixed assets compared to its total assets. However, it is vital for Pfizer Inc to monitor and manage these ratios effectively to ensure optimal asset utilization and revenue generation in the long term.
See also:
Pfizer Inc Long-term (Investment) Activity Ratios (Quarterly Data)